

Purified anti-human CD3 Antibody

Catalog# / Size	317301 / 25 µg 317302 / 100 µg
Clone	OKT3
Regulatory Status	RUO
Workshop	HCDM listed
Other Names	T3, CD3ε
Isotype	Mouse IgG2a, κ
Description	CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details

Verified Reactivity	Human
Antibody Type	Monoclonal
Host Species	Mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested IHC-F - Reported in the literature. not verified in house
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex. Clone OKT3 can block the binding of clones SK7 and UCHT1. ⁴ The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References	<ol style="list-style-type: none"> Schlossman S, <i>et al.</i> Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York. Barclay N, <i>et al.</i> 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego. Li B, <i>et al.</i> 2005. <i>Immunology</i> 116:487. Jeong HY, <i>et al.</i> 2008. <i>J. Leucocyte Biol.</i> 83:755. PubMed Alter G, <i>et al.</i> 2008. <i>J. Virol.</i> 82:9668. PubMed Manevich-Mendelson E, <i>et al.</i> 2009. <i>Blood</i> 114:2344. PubMed Pinto JP, <i>et al.</i> 2010. <i>Immunology.</i> 130:217. PubMed Biggs MJ, <i>et al.</i> 2011. <i>J. R. Soc. Interface.</i> 8:1462. PubMed
(PubMed link indicates BioLegend citation)	

Product Citations

1. Winkler M, *et al.* 2017. PLoS One. 10.1371/journal.pone.0182427. [PubMed](#)
2. Qiu H, *et al.* 2017. Exp Cell Res. 10.1016/j.yexcr.2017.08.036. [PubMed](#)
3. Lang C, Wang J, and Chen L 2017. Exp Cell Res. 10.1016/j.yexcr.2017.09.030. [PubMed](#)
4. Thomi R, *et al.* 2017. Br J Dermatol. 10.1111/bjd.15458. [PubMed](#)
5. Jin Y, *et al.* 2017. Int Immunopharmacol. 10.1016/j.intimp.2017.10.009. [PubMed](#)
6. Pawlak EN, *et al.* 2018. Retrovirology. 15:6. [PubMed](#)
7. Yarzabek B *et al.* 2018. eLife. 7 pii: e34961. [PubMed](#)
8. Broos K, *et al.* 2019. Cancers (Basel). 11. [PubMed](#)
9. Xiong Y, *et al.* 2019. J Immunol. 203:3023. [PubMed](#)
10. Dutertre CA, *et al.* 2020. Immunity. 51(3):573-589.e8. [PubMed](#)
11. Alcántara-Hernández M *et al.* 2017. Immunity. 47(6):1037-1050. [PubMed](#)
12. Nissim L *et al.* 2017. Cell. 171(5):1138-1150. [PubMed](#)
13. Schoknecht T, *et al.* 2017. J Leukoc Biol. 101:589. [PubMed](#)
14. Crome SQ, *et al.* 2017. Nat Med. 1.213888889. [PubMed](#)
15. Kessel C, *et al.* 2017. Arthritis Rheumatol. 69:1480. [PubMed](#)
16. Singh AK, *et al.* 2017. Front Immunol. 0.513888889. [PubMed](#)
17. García-Ortiz A, *et al.* 2017. PLoS Biol. 15:e2000653. [PubMed](#)
18. Liu Z, *et al.* 2017. Oncotarget. 8:53518. [PubMed](#)
19. Horn LA, *et al.* 2017. Oncotarget. 8:57964. [PubMed](#)
20. Johnston HE, *et al.* 2018. Mol Cell Proteomics. 1.247222222. [PubMed](#)
21. Bae EA, *et al.* 2018. Cancer Res. 78:5315. [PubMed](#)
22. Meng Q, *et al.* 2018. Sci Rep. 8:17079. [PubMed](#)
23. Mayer KE, *et al.* 2019. Theranostics. 4.548611111. [PubMed](#)
24. Escudero-Pérez B, *et al.* 2019. JCI Insight. 4:e126070. [PubMed](#)
25. Terzuoli E, *et al.* 2019. Cancers (Basel). 1.821527778. [PubMed](#)
26. Sneddon S, *et al.* 2020. Oncoimmunology. 9:1684713. [PubMed](#)
27. Seo N, *et al.* 2018. Nat Commun. 9:435. [PubMed](#)
28. Liang J, *et al.* 2017. Nat Commun. 8:15732. [PubMed](#)
29. Auladell M, *et al.* 2019. Clin Transl Immunology. 8:e01090. [PubMed](#)
30. Ardain A, *et al.* 2019. Nature. 570:528. [PubMed](#)
31. Boutboul D, *et al.* 2018. J Clin Invest. 128:3071. [PubMed](#)
32. Bluhm J, *et al.* 2018. Mol Ther. 26:1906. [PubMed](#)
33. Holbrook AK, *et al.* 2019. Physiol Rep. 7:e14234. [PubMed](#)
34. Caielli S, *et al.* 2019. Nat Med. 25:75. [PubMed](#)
35. Chevalier MF, *et al.* 2017. J Clin Invest. 127:2916. [PubMed](#)
36. Benabdallah B, *et al.* 2019. Front Immunol. 10:2580. [PubMed](#)
37. Hashimoto M, *et al.* 2017. Int J Inflamm. 2017:1324735. [PubMed](#)
38. Yin Y, *et al.* 2017. J Allergy Clin Immunol. 139:1701. [PubMed](#)
39. Willing A, *et al.* 2018. J Immunol. 200:974. [PubMed](#)
40. Tripathi T, *et al.* 2019. Immunohorizons. 0.201388889. [PubMed](#)
41. Kujawski M, *et al.* 2019. BMC Cancer. 1.404166667. [PubMed](#)
42. Ghosh S, *et al.* 2020. Cell Reports. 30(10):3434-3447. [PubMed](#)
43. Walk J, *et al.* 2020. Front Immunol. 2.405555556. [PubMed](#)
44. Zhao R, *et al.* 2018. Oncoimmunology. 8:e1509173. [PubMed](#)
45. Mehta N, *et al.* 2020. Sci Rep. 10:15171. [PubMed](#)
46. Leylek R, *et al.* 2020. Cell Rep. 32:108180. [PubMed](#)
47. Bertino P, *et al.* 2019. Oncoimmunology. 8:1601482. [PubMed](#)
48. Mousset CM, *et al.* 2018. Oncoimmunology. 7:e1488565. [PubMed](#)
49. Siegers GM, *et al.* 2020. Front Immunol. 1.352083333. [PubMed](#)
50. Alter G, *et al.* 2008. J Virol. 82:9668. [PubMed](#)
51. Jeong H, *et al.* 2008. J Leukoc Biol. 83:755. [PubMed](#)
52. Manevich-Mendelson E, *et al.* 2009. Blood. 114:2344. [PubMed](#)
53. Biggs M, *et al.* 2011. J R Soc Interface. 1.348611111. [PubMed](#)
54. Pinto J, *et al.* 2010. Immunology. 130:217. [PubMed](#)
55. Blas-Rus N, *et al.* 2016. Nat Commun. 7: 11389. [PubMed](#)
56. Barzilai S, *et al.* 2017. Cell Rep. 18(3):685-699. [PubMed](#)
57. Welch JL, *et al.* 2020. FEBS Lett. 594:695. [PubMed](#)
58. Zavidij O, *et al.* 2020. Nat Cancer. 0.384027778. [PubMed](#)
59. Hsu CY, *et al.* 2020. Frontiers in Immunology. 11:574839. [PubMed](#)
60. Hu X, *et al.* 2021. British Journal of Pharmacology. 178(6):1445-1458. [PubMed](#)
61. He Y, *et al.* 2021. eLife. 10:00. [PubMed](#)
62. Srivastava S, *et al.* 2020. Cancer Cell. 39(2):193-208.e10. [PubMed](#)
63. Chevrier S, *et al.* 2021. Cell Reports Medicine. 2(1):100166. [PubMed](#)
64. Kaufmann M, *et al.* 2021. Med. 2(3):296-312.e8. [PubMed](#)
65. Herati RS, *et al.* 2021. Cell Reports Medicine. 2(5):100262. [PubMed](#)
66. Henrick BM, *et al.* 2021. Cell. [PubMed](#)

RRID

AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure

Ig superfamily, the subunits CD3 γ , CD3 δ , CD3 ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD

Distribution

Mature T and NK T cells, thymocyte differentiation

Function	Antigen recognition, signal transduction, T cell activation
Ligand/Receptor	Peptide antigen bound to MHC
Cell Type	NKT cells, T cells, Thymocytes, Tregs
Biology Area	Immunology
Molecular Family	CD Molecules

Antigen References

1. Barclay N, *et al.* 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, *et al.* 1981. *Eur. J. Immunol.* 11:329.
3. Lanier L, *et al.* 1986. *J. Immunol.* 137:2501.

Gene ID [916](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Purified anti-human CD3, FITC anti-human CD3, PE anti-human CD3, Alexa Fluor® 488 anti-human CD3, Alexa Fluor® 647 anti-human CD3, Pacific Blue™ anti-human CD3, APC anti-human CD3, Biotin anti-human CD3, Brilliant Violet 605™ anti-human CD3, Brilliant Violet 650™ anti-human CD3, Ultra-LEAF™ Purified anti-human CD3, Brilliant Violet 711™ anti-human CD3, Brilliant Violet 785™ anti-human CD3, Brilliant Violet 510™ anti-human CD3, PE/Cyanine7 anti-human CD3, PerCP/Cyanine5.5 anti-human CD3, PerCP anti-human CD3, Alexa Fluor® 700 anti-human CD3, APC/Cyanine7 anti-human CD3, Brilliant Violet 421™ anti-human CD3, PE/Dazzle™ 594 anti-human CD3, APC/Fire™ 750 anti-human CD3, GMP Ultra-LEAF™ Purified anti-human CD3 SF, PE/Cyanine5 anti-human CD3 Antibody

Product Data



Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-BioLegend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587